PP
ABUS icon

Paloma Partners’s Arbutus Biopharma ABUS Stock Holding History

Paloma Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,978
Closed -$57K – 1065
2022
Q1 		$57K Buy
18,978
+6,447
+51% +$19.7K ﹤0.01% 1657
2021
Q4 		$49K Buy
+12,531
New +$48.7K ﹤0.01% 1831
2020
Q1 		– Sell
-19,674
Closed -$55K – 1174
2019
Q4 		$55K Buy
+19,674
New +$31.8K ﹤0.01% 2076
2019
Q3 		– Sell
-157,300
Closed -$327K – 1900
2019
Q2 		$327K Buy
+157,300
New +$402K 0.01% 1249

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's ABUS Position: Q2 2022 in Review

Paloma Partners sold out of Arbutus Biopharma (ABUS) in Q2 2022, closing a stake of 18,978 shares — an estimated $57K sold.

Paloma Partners first reported a position in ABUS in Q2 2019 and held it in 4 quarters. The position peaked at $327K in Q2 2019. 113 funds tracked by Wall St. Rank hold ABUS as of Q2 2022.

  • Paloma Partners reported no remaining Arbutus Biopharma position as of Q2 2022 after selling out during the quarter.
  • Paloma Partners sold 18,978 Arbutus Biopharma shares in Q2 2022, an estimated $57K.
  • Paloma Partners first reported a position in Arbutus Biopharma in Q2 2019 and held it in 4 quarters.
  • Paloma Partners's Arbutus Biopharma position peaked at $327K in Q2 2019.
  • 113 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2022.

Based on Paloma Partners's 13F filing for Q2 2022, filed 15 Aug 2022.